Does ERDAFITINIB Cause Malignant neoplasm progression? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Malignant neoplasm progression have been filed in association with ERDAFITINIB (BALVERSA). This represents 1.5% of all adverse event reports for ERDAFITINIB.
16
Reports of Malignant neoplasm progression with ERDAFITINIB
1.5%
of all ERDAFITINIB reports
6
Deaths
6
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ERDAFITINIB?
Of the 16 reports, 6 (37.5%) resulted in death, 6 (37.5%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ERDAFITINIB. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does ERDAFITINIB Cause?
Death (255)
Off label use (86)
Diarrhoea (75)
Stomatitis (58)
Fatigue (45)
Onycholysis (44)
Disease progression (41)
Dry mouth (41)
Nail disorder (40)
Hyperphosphataemia (39)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ERDAFITINIB Alternatives Have Lower Malignant neoplasm progression Risk?
ERDAFITINIB vs ERENUMAB
ERDAFITINIB vs ERENUMAB-AOOE
ERDAFITINIB vs ERENUMAB\ERENUMAB-AOOE
ERDAFITINIB vs ERGOCALCIFEROL
ERDAFITINIB vs ERGOCALCIFEROL\PHYTONADIONE\RETINOL\TOCOPHEROL